Drug And Gene Delivery Devices Market Report

Drug And Gene Delivery Devices Market Analysis By Drug Delivery Type (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical), By Gene Delivery Vector (Viral, Non-viral), By Gene Delivery Type (In situ, Ex vivo), And Segment Forecasts, 2014 - 2025

Published: December 2016  |  90 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-238-9

Industry Insights

The global drug and gene delivery system market size was valued at USD 379.2 Billion in 2015. Growing efforts towards formulating dosage forms that would help in maximizing the bioavailability of the drug at the target site while increasing the patient convenience are driving the global market growth. The introduction of the novel drug delivery systems such as subdermal implants that are available in different forms such as rings and patches are expected to aid in the industry growth.

The evolution of the drug delivery systems is directly attributed to changing preferences by patients as well as healthcare professionals. A few of the many advancements include-

     • Introduction of Biopharmaceutical classification systems (BCS) class II drug in oral dosage forms
     • Introduction of auto-injectors
     • Availability of advanced implants in customized shapes and sizes
     • Introduction of advanced pulmonary devices such as Smartcard and Adaptive Aerosol Delivery

Japan drug delivery systems market, by route of administration, 2014 - 2025 (USD Billion)

Japan drug delivery systems market

Route of Administration Insights

Based on the route of administration, the report is segmented into oral, inhalation, transdermal, injectable, ocular, nasal, and topical. Oral segment captured the largest share in 2015. Pharmaceutical companies are focusing on reducing the amount of API per dose and increase the bioavailability at the site of action.

The potency and safety of biotechnology agents are attracting the biopharmaceutical companies to invest largely in research and development of these drugs. These biological drugs are rapidly replacing their traditional counterparts and most of the them are prone to deterioration by oral route; thus injectable drug delivery is a preferred route of administration. Additionally, the advancements in injectable devices which enable the convenient self-injection by the patients are some of the factors expected to fuel the growth of the injectable segment during the forecast period.

Methods Insights

Based on the method used, gene delivery system is segmented as in situ and ex vivo. Most of the currently approved drugs act by in situ methods. Thus, the in situ segment is currently dominating the industry with the largest share.

High focus on the in situ methods owing to its ease of performance is expected to make it the fastest growing segment in the space. However, the segment growth is expected to impede by the low efficiency of transduction procedures.

Vector Insights

Viral vectors currently dominate the gene delivery systems market with 4 approved drugs. More than 60% of the ongoing clinical trials on gene therapies are based on the viral vectors for transfection. Thus, the viral segment is expected to remain dominant throughout the forecast period.

Viral vectors enable complex procedures involved in transfection procedures such as gene gun, magnetofection, ultrasound, and hydrodynamic. In addition, it has increased the success rate of the gene transfer as compared to its counterpart techniques.

Global gene delivery systems market, by vector, 2015 (%)

Global gene delivery systems market

Regional Insights

North America captured the largest market share in 2015. The presence of a large number of key players and high adoption rate of the advanced methods are the factors driving the industry growth in the region. In addition, high investment on R&D by the U.S. government and industry participants are augmenting the industry growth of the region.

Asia Pacific is expected to show a lucrative growth rate during the forecast period owing to the factors such as growing awareness about the novel systems as well as the influx of the international industry players to seek the opportunities in the untapped market in the region.

Competitive Insights

Major players in the drug delivery systems market include but are not limited to Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, and Becton, Dickinson and Company. These companies are constantly investing in the product development to cater to the changing demands of the patients and to maintain their position in the competition.

Key players operating in the gene delivery systems include Uniqure N.V., SiBiono GeneTech Co., Epeius Biotechnologies Corporation, Shanghai Sunway Biotech Co., Ltd, and Human Stem Cells Institute. These companies are also engaged in the R&D of their products to explore further applications in the different physiological conditions.

Report Scope           

Attribute

Details

Base year for estimation

2015

Actual estimates/Historical data

2014 - 2015

Forecast period

2016 - 2025

Market representation

Revenue in USD Billion & CAGR from 2016 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America & MEA

Country scope

U.S., Canada, UK, Germany, Japan, China, Brazil, Mexico, South Africa

Report coverage             

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the drug and gene delivery systems market on the basis of route of administration, vectors, methods, and region:

  • Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)

    • Oral

    • Inhalation

    • Transdermal

    • Injectable

    • Ocular

    • Nasal

    • Topical

  • Vector Outlook (Revenue, USD Million 2014 - 2025)

    • Viral

    • Non-viral

  • Method Outlook (Revenue, USD Million 2014 - 2025)

    • In situ

    • Ex vivo

  • Regional Outlook (Revenue, USD Billion, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Mexico

      • Brazil

    • MEA

      • South Africa

Request Sample
Request for Customization

Choose License Type:

Single User - $4,950
Multi User - $7,950
Enterprise User - $9,950

Special Pricing & Discounts

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA